Terms: = Germ cell tumor AND ATRX, P46100, ZNF-HX, XNP, XH2, SHS, SFM1, RAD54, MRXHF1, MGC2094, ATR2, 546 AND Clinical Outcome
22 results:
1. MYCN amplification, TERT rearrangements and atrx mutations in neuroblastoma: clinicopathological correlates- an Indian perspective.
Kerkar AN; Chinnam D; Verma A; Peters NJ; Kakkar N; Trehan A; Singh M; Gupta K
Virchows Arch; 2023 Oct; 483(4):477-486. PubMed ID: 37460674
[TBL] [Abstract] [Full Text] [Related]
2. H3K27M-Altered Diffuse Midline Gliomas Among Adult Patients: A Systematic Review of clinical Features and Survival Analysis.
Bin-Alamer O; Jimenez AE; Azad TD; Bettegowda C; Mukherjee D
World Neurosurg; 2022 Sep; 165():e251-e264. PubMed ID: 35697228
[TBL] [Abstract] [Full Text] [Related]
3. Can a signature molecular-profile define disparate survival in BRAF-positive Gliosarcoma and identify novel targets for therapeutic intervention?
Gandhi P; Khare R; Garg N; Mishra J
J Cancer Res Ther; 2022; 18(1):224-230. PubMed ID: 35381788
[TBL] [Abstract] [Full Text] [Related]
4. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.
Suwala AK; Stichel D; Schrimpf D; Kloor M; Wefers AK; Reinhardt A; Maas SLN; Kratz CP; Schweizer L; Hasselblatt M; Snuderl M; Abedalthagafi MSJ; Abdullaev Z; Monoranu CM; Bergmann M; Pekrun A; Freyschlag C; Aronica E; Kramm CM; Hinz F; Sievers P; Korshunov A; Kool M; Pfister SM; Sturm D; Jones DTW; Wick W; Unterberg A; Hartmann C; Dodgshun A; Tabori U; Wesseling P; Sahm F; von Deimling A; Reuss DE
Acta Neuropathol; 2021 Jan; 141(1):85-100. PubMed ID: 33216206
[TBL] [Abstract] [Full Text] [Related]
5. Infratentorial IDH-mutant astrocytoma is a distinct subtype.
Banan R; Stichel D; Bleck A; Hong B; Lehmann U; Suwala A; Reinhardt A; Schrimpf D; Buslei R; Stadelmann C; Ehlert K; Prinz M; Acker T; Schittenhelm J; Kaul D; Schweizer L; Capper D; Harter PN; Etminan N; Jones DTW; Pfister SM; Herold-Mende C; Wick W; Sahm F; von Deimling A; Hartmann C; Reuss DE
Acta Neuropathol; 2020 Oct; 140(4):569-581. PubMed ID: 32776277
[TBL] [Abstract] [Full Text] [Related]
6. Telomere Maintenance Mechanisms Define clinical outcome in High-Risk Neuroblastoma.
Koneru B; Lopez G; Farooqi A; Conkrite KL; Nguyen TH; Macha SJ; Modi A; Rokita JL; Urias E; Hindle A; Davidson H; Mccoy K; Nance J; Yazdani V; Irwin MS; Yang S; Wheeler DA; Maris JM; Diskin SJ; Reynolds CP
Cancer Res; 2020 Jun; 80(12):2663-2675. PubMed ID: 32291317
[TBL] [Abstract] [Full Text] [Related]
7. Pineal Gland tumor Microenvironment.
Choque-Velasquez J; Baluszek S; Colasanti R; Muhammad S; Hernesniemi J
Adv Exp Med Biol; 2020; 1296():137-150. PubMed ID: 34185290
[TBL] [Abstract] [Full Text] [Related]
8. atrx, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup.
Chan CS; Laddha SV; Lewis PW; Koletsky MS; Robzyk K; Da Silva E; Torres PJ; Untch BR; Li J; Bose P; Chan TA; Klimstra DS; Allis CD; Tang LH
Nat Commun; 2018 Oct; 9(1):4158. PubMed ID: 30315258
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic significance of genetic biomarkers in isocitrate dehydrogenase-wild-type lower-grade glioma: the need to further stratify this tumor entity - a meta-analysis.
Vuong HG; Tran TTK; Ngo HTT; Pham TQ; Nakazawa T; Fung KM; Hassell L; Katoh R; Kondo T
Eur J Neurol; 2019 Mar; 26(3):379-387. PubMed ID: 30298540
[TBL] [Abstract] [Full Text] [Related]
10. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and atrx alterations.
Reinhardt A; Stichel D; Schrimpf D; Sahm F; Korshunov A; Reuss DE; Koelsche C; Huang K; Wefers AK; Hovestadt V; Sill M; Gramatzki D; Felsberg J; Reifenberger G; Koch A; Thomale UW; Becker A; Hans VH; Prinz M; Staszewski O; Acker T; Dohmen H; Hartmann C; Mueller W; Tuffaha MSA; Paulus W; Heß K; Brokinkel B; Schittenhelm J; Monoranu CM; Kessler AF; Loehr M; Buslei R; Deckert M; Mawrin C; Kohlhof P; Hewer E; Olar A; Rodriguez FJ; Giannini C; NageswaraRao AA; Tabori U; Nunes NM; Weller M; Pohl U; Jaunmuktane Z; Brandner S; Unterberg A; Hänggi D; Platten M; Pfister SM; Wick W; Herold-Mende C; Jones DTW; von Deimling A; Capper D
Acta Neuropathol; 2018 Aug; 136(2):273-291. PubMed ID: 29564591
[TBL] [Abstract] [Full Text] [Related]
11. [Update on the 2016 WHO classification of tumors of the central nervous system - Part 1: Diffusely infiltrating gliomas].
Švajdler M; Rychlý B; Zámečník J; Švajdler P
Cesk Patol; 2017; 53(1):12-21. PubMed ID: 28248117
[TBL] [Abstract] [Full Text] [Related]
12. Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future.
Ohmoto A; Rokutan H; Yachida S
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28098761
[TBL] [Abstract] [Full Text] [Related]
13. Classification of adult diffuse gliomas by molecular markers-a short review with historical footnote.
Otani R; Uzuka T; Ueki K
Jpn J Clin Oncol; 2017 Jan; 47(1):2-6. PubMed ID: 27799281
[TBL] [Abstract] [Full Text] [Related]
14. atrx immunostaining predicts IDH and H3F3A status in gliomas.
Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J
Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324
[TBL] [Abstract] [Full Text] [Related]
15. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach.
Rajmohan KS; Sugur HS; Shwetha SD; Ramesh A; Thennarasu K; Pandey P; Arivazhagan A; Santosh V
J Clin Pathol; 2016 Aug; 69(8):686-94. PubMed ID: 26743027
[TBL] [Abstract] [Full Text] [Related]
17. atrx loss in adult supratentorial diffuse astrocytomas correlates with p53 over expression and IDH1 mutation and predicts better outcome in p53 accumulated patients.
Shao LW; Pan Y; Qi XL; Li YX; Ma XL; Yi WN; Zhang J; Zhong YF; Chang Q
Histol Histopathol; 2016 Jan; 31(1):103-14. PubMed ID: 26395639
[TBL] [Abstract] [Full Text] [Related]
18. Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors.
Mangerel J; Price A; Castelo-Branco P; Brzezinski J; Buczkowicz P; Rakopoulos P; Merino D; Baskin B; Wasserman J; Mistry M; Barszczyk M; Picard D; Mack S; Remke M; Starkman H; Elizabeth C; Zhang C; Alon N; Lees J; Andrulis IL; Wunder JS; Jabado N; Johnston DL; Rutka JT; Dirks PB; Bouffet E; Taylor MD; Huang A; Malkin D; Hawkins C; Tabori U
Acta Neuropathol; 2014 Dec; 128(6):853-62. PubMed ID: 25315281
[TBL] [Abstract] [Full Text] [Related]
19. Olig2 labeling index is correlated with histological and molecular classifications in low-grade diffuse gliomas.
Suzuki A; Nobusawa S; Natsume A; Suzuki H; Kim YH; Yokoo H; Nagaishi M; Ikota H; Nakazawa T; Wakabayashi T; Ohgaki H; Nakazato Y
J Neurooncol; 2014 Nov; 120(2):283-91. PubMed ID: 25085214
[TBL] [Abstract] [Full Text] [Related]
20. atrx mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples.
Cai J; Yang P; Zhang C; Zhang W; Liu Y; Bao Z; Liu X; Du W; Wang H; Jiang T; Jiang C
Oncotarget; 2014 May; 5(9):2551-61. PubMed ID: 24810474
[TBL] [Abstract] [Full Text] [Related]
[Next]
